BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24531162)

  • 1. Predicting the time to clinically worsening in mild cognitive impairment patients and its utility in clinical trial design by modeling a longitudinal clinical dementia rating sum of boxes from the ADNI database.
    Ito K; Hutmacher MM
    J Alzheimers Dis; 2014; 40(4):967-79. PubMed ID: 24531162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment.
    Dickerson BC; Sperling RA; Hyman BT; Albert MS; Blacker D
    Arch Gen Psychiatry; 2007 Dec; 64(12):1443-50. PubMed ID: 18056553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
    Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
    Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.
    Cedarbaum JM; Jaros M; Hernandez C; Coley N; Andrieu S; Grundman M; Vellas B;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S45-55. PubMed ID: 22658286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
    Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
    J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database.
    O'Bryant SE; Lacritz LH; Hall J; Waring SC; Chan W; Khodr ZG; Massman PJ; Hobson V; Cullum CM
    Arch Neurol; 2010 Jun; 67(6):746-9. PubMed ID: 20558394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.
    Besser LM; Litvan I; Monsell SE; Mock C; Weintraub S; Zhou XH; Kukull W
    Parkinsonism Relat Disord; 2016 Jun; 27():54-60. PubMed ID: 27089852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of the Clinical Dementia Rating Scale Sum of Boxes in Staging and Detection of Cognitive Impairment in Mexican Americans.
    Julayanont P; DeToledo JC
    J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):128-134. PubMed ID: 33261535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.
    Samtani MN; Raghavan N; Novak G; Nandy P; Narayan VA
    Neuropsychiatr Dis Treat; 2014; 10():929-52. PubMed ID: 24926196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operational Determination of Subjective Cognitive Decline, Mild Cognitive Impairment, and Dementia Using Sum of Boxes of the Clinical Dementia Rating Scale.
    Yang YW; Hsu KC; Wei CY; Tzeng RC; Chiu PY
    Front Aging Neurosci; 2021; 13():705782. PubMed ID: 34557083
    [No Abstract]   [Full Text] [Related]  

  • 16. Can the Clinical Dementia Rating Scale Identify Mild Cognitive Impairment and Predict Cognitive and Functional Decline?
    Woolf C; Slavin MJ; Draper B; Thomassen F; Kochan NA; Reppermund S; Crawford JD; Trollor JN; Brodaty H; Sachdev PS
    Dement Geriatr Cogn Disord; 2016; 41(5-6):292-302. PubMed ID: 27332560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale-Sum of Boxes.
    Grober E; Qi Q; Kuo L; Hassenstab J; Perrin RJ; Lipton RB
    J Alzheimers Dis; 2021; 80(1):185-195. PubMed ID: 33492286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal clinically important difference in Alzheimer's disease: Rapid review.
    Muir RT; Hill MD; Black SE; Smith EE
    Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
    Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.